Durvalumab Does Not Worsen Quality of Life Among Patients With Unresectable NSCLC
During a plenary presentation at the 18th annual WCLC, researchers presented patient-reported outcomes, including health-related QoL, disease symptoms, and physical function, from the phase 3 PACIFIC
|The following article features coverage from the IASLC 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan. Click here to read more of Cancer Therapy Advisor's conference coverage.|
Compared with placebo, durvalumab does not worsen health-related quality of life (QoL) among patients with advanced non–small cell lung cancer (NSCLC), according to a plenary presentation at the International Association for the Study of Lung Cancer (IASLC) 18th Annual World Conference on Lung Cancer (WCLC) in Yokohama, Japan.1
Results from the phase 3 PACIFIC trial (ClinicalTrials.gov Identifier: NCT02125461) were previously reported, showing that durvalumab, a PD-L1 inhibitor, improves progression-free survival among patients with stage III unresectable NSCLC. All patients previously received at least 2 cycles of chemoradiation, did not have disease progression, and were randomly assigned 2:1 to receive durvalumab (476 patients) or placebo (237 patients).
All patients were asked to complete questionnaires at week 4, week 8, every 8 weeks thereafter until week 48, and every 12 weeks until disease progression. Researchers used these data to present patient-reported outcomes, including health-related QoL, disease symptoms, and function, from PACIFIC.
At week 48, more than 80% of patients complied with questionnaire completion. Baseline health-related QoL, symptoms, and function data were similar between the groups. The authors noted that there were “no statistically significant differences between treatment groups in adjusted mean changes from baseline (average over 12 months) in the prespecified symptoms of dyspnea, cough, chest pain, fatigue and appetite loss, and for global health status/QoL and physical functioning.”
Dysphagia and alopecia, which were likely related to prior chemotherapy, improved at similar rates in both groups.
Patients who received placebo, however, had a time to deterioration of 5.6 months for “other pain” compared with 9.2 months with durvalumab (hazard ratio, 0.72). Patients who received durvalumab also had a 26.1% appetite-loss improvement rate compared with 24.9% with placebo (odds ratio, 1.72).
The authors concluded that patients who received durvalumab did not have worse disease symptoms, physical function, or health-related QoL compared with those who received placebo.
Read more of Cancer Therapy Advisor's coverage of the IASLC 18th World Conference on Lung Cancer (WCLC) by visiting the conference page.
- Hui R, Özgüroğlu M, Daniel D. Patient-reported outcomes with durvalumab after chemoradiation in locally advanced, unresectable NSCLC: data from PACIFIC. Presented at: International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer; Yokohama, Japan: October 15-18, 2017. Abstract PL 02.02.